title: [Is there a place for interferon-alpha in the treatment strategy of multicentric Castleman's disease?].
abstract: BACKGROUND
  Castleman's disease is an unusual condition of unknown cause, consisting of massive proliferation of lymphoid tissue. Two forms (localized and multicentric) have been described. Interleukin-6 (IL-6) is at the core of the disease, being responsible for most of the clinical and biological signs that may be observed. Despite the benignancy of this pre-lymphoma condition, its course is usually aggressive and of poor prognosis in regard to the multicentric form. No consensus regarding treatment has been defined. Available data on the multicentric form of the disease are to scarce to allow any conclusion about the treatment timing and type of chemotherapy best suited to this condition. We report the case of a patient in whom interferon alpha (IFN-alpha) was used as first line treatment.
  
  
  METHODS
  The case of a 52-year-old man with multicentric Castleman's disease combined with high IL-6, in whom, however, testing for human herpes virus-8 proved to be negative, is described. Interferon alpha (4.5 MU/m2 three times per week during 18 months) administered as first line treatment induced dramatic improvement in the patient's general condition and normalization of the tumoral syndrome. Moreover, biological parameters and IL-6 returned to normal. Two years after interferon disruption, complete remission is still present.
  
  
  CONCLUSIONS
  On the basis of the present data and those of two previous observations, anti-IL-6 and anti-infective properties of IFN-alpha are discussed. Treatment of multicentric Castleman's disease is based on corticosteroids and drugs derived from those pertaining to treatment of malignant lymphomas. Our results indicate that IFN-alpha is truly directed against Castleman's disease and has less toxicity than drugs usually prescribed. This argues for early use of IFN-alpha in Castleman's disease, in association or not with corticosteroids.
authors.affiliation: Service d'onco-hématologie, hôpital de Hautepierre, Strasbourg, France.
authors.forename: F
authors.initials: F
authors.lastname: Maloisel
authors.forename: E
authors.initials: E
authors.lastname: Andrès
authors.forename: F
authors.initials: F
authors.lastname: Campos
authors.forename: C
authors.initials: C
authors.lastname: Opréa
authors.forename: M
authors.initials: M
authors.lastname: Deslandres
authors.forename: R
authors.initials: R
authors.lastname: Randriamahazaka
authors.forename: J E
authors.initials: JE
authors.lastname: Kurtz
authors.forename: A
authors.initials: A
authors.lastname: Koumarianou
authors.forename: P
authors.initials: P
authors.lastname: Dufour
mesh_terms: D005871:Castleman Disease / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000188:drug therapy; D011379:Prognosis
chemical_list: D007155:Immunologic Factors; D016898:Interferon-alpha; D015850:Interleukin-6
vernacular_title: Y a-t-il une place pour l'interféron-alpha dans la stratégie thérapeutique de la maladie de Castleman multicentrique?